Trial Profile
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Plasmablastic lymphoma; Primary-Effusion-Lymphoma
- Focus Adverse reactions; Therapeutic Use
- 23 Feb 2022 Status changed from active, no longer recruiting to completed.
- 19 May 2020 Results of median follow-up (as of 30 July 2019) of 40 months published in the Blood
- 06 Nov 2019 Results of post0hoc analysis released in the 61st Annual Meeting and Exposition of the American Society of Hematology.